生物帮生物通

采购帮忙热线
020-87540820
020-38498013
 
当前位置: 首页 » 行业资讯 » 行业资讯 » 正文

罗氏在RNA药物领域再发力与Santaris建立合作

放大字体  缩小字体 发布日期:2014-01-14  浏览次数:7
公司介绍:罗氏诊断产品(上海)有限公司


-三年前,制药巨头罗氏公司决定投入5亿美元用于发展RNA类药物,不过很快公司就发现在这一领域公司面临的困难可能远远超出想象。不过现在罗氏公司决定卷土重来,并与Santaris公司进行战略合作。根据协议,公司首先将投入1000万美元支持此次研究计划,同时还设立了总额高达1亿3千8百万美元的里程碑基金。与此同时,Santaris公司最近也刚刚宣布公司也和葛兰素史克公司以及施贵宝公司建立了研发合作关系。

在这次合作中,罗氏公司将借助Santaris公司的LNA平台来进行相关的RNAi药物研发。Santaris公司称LNA平台能够克服抗体、siRNA难以输送的缺点。罗氏公司与Santaris公司都对这一平台寄予了极大希望,希望能够帮助其取得在RNA药物研究方面的突破。

 

Jan 9, 2014

Roche to Use Santaris' LNA Platform in RNA-Targeted Alliance

  • Santaris Pharma said today it joined Roche in launching an up-to-$148 million-plus-per-product alliance designed to discover and develop RNA-targeted oligonucleotide therapeutics using Santaris’locked nucleic acid (LNA) drug platform—just over two months after Santaris won back the technology from a former partner in a terminated cancer drug collaboration.

    The companies said they will collaborate on discovering LNA drugs against “a multitude of” targets across “several” disease areas, without offering further specifics.

    Santaris’ LNA platform and companion drug discovery engine combine the company's LNA chemistry with drug-development capabilities intended to rapidly deliver LNA-based drug candidates against both mRNA and microRNA. The platform is designed to overcome limitations associated with earlier antisense and siRNA technologies, using small size and high affinity to inhibit RNA targets in several different tissues without the need for more complex delivery vehicles.

    The new collaboration with Roche could net Santaris up to $148 million-plus per product developed. Roche agreed to pay the Danish company $10 million up front, as well as up to $138 million in payments tied to preclinical, clinical, regulatory, and sales milestones per product, and funding of ongoing discovery and research activities. Santaris will also be eligible for royalties on worldwide sales of all medicines arising from the alliance.

    “This is a very important deal to Santaris, and we look forward to working closely with the Roche teams in our joint pursuit of novel, breakthrough drugs,” Santaris President and CEO Don deBethizy, Ph.D., said in a statement.

    The deal is also important to Roche, which a year ago this month named John C. Reed, M.D., Ph.D., the CEO of the nonprofit Sanford-Burnham Medical Research Institute, to head its pharma research and early development (pRED) unit, with the goal to reverse the company’s struggle in recent years to translate pipeline drugs into Phase III successes that can win marketing approvals and reach patients.

    “We believe the LNA drug platform provides the means to discover novel drugs against a range of targets of high clinical relevance that are difficult—or impossible—to target with other drug platforms,” Dr. Reed said. “The partnership will increase our ability to discover and develop important novel medicines that can address significant unmet needs in critical therapeutic areas."

    Santaris licensed the LNA technology to Enzon Pharmaceuticals under a seven-year-old cancer drug collaboration that could have netted Santaris more than $200 million. In 2012, Enzon substantially suspended clinical development activities and sought to sell its interest in the LNA technology for $100,000 to Belrose Pharma, but a planned sale fell through, Enzon disclosed August 6 in a regulatory filing.

    Last October, Santaris and Enzon came to terms on the termination, with Enzon reverting full LNA rights back to Santaris, and paying Santaris an undisclosed amount of money, while both companies agreed to release all claims against the other.

    Founded in 2003, Santaris holds exclusive worldwide rights to manufacture, have manufactured, and sell products containing LNA as an active ingredient, for studies performed with a view to obtaining marketing approval. The company’s research focuses on therapeutic areas that include cardiometabolic disorders, infectious and inflammatory diseases, cancers, and rare genetic disorders.

    Roche joins a parade of biopharma giants collaborating with Santaris. The list includes Bristol-Myers Squibb, miRagen Therapeutics, Pfizer, RaNa Therapeutics, Shire, and Isarna Therapeutics.

 
 
[ 行业资讯搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

0条 [查看全部]  相关评论

 
推荐行业资讯
点击排行
 
网站首页 | 企业资料认证流程 | 广告服务 | 关于我们 | 联系方式 | 使用协议 | 网站地图 | 排名推广 | 广告服务 | 网站留言 | RSS订阅 | 粤ICP备11050685号-8